Importantly, experimental validation demonstrated that silencing the CR TFF1 inhibited tumor growth and reduced the malignant behavior of LUAD cells in vitro and in vivo, indicating that TFF1 may be a promising therapeutic target for lung cancer treatment. Here, TFF1 is linked to lung carcinoma.